Literature DB >> 33544119

Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?

Ciaran Judge1,2, Reza Saeidi1,3, Kathleen Sugrue1,2, Louise Rabbitt1,4, Aine Keogh1,4, Clodagh Byron1,5, Syed Akbar Zulquernain1,5, Sarah Gleeson1,2, Aoibhlinn O'Toole1,6, Martin Buckley1,2, Eoin Slattery1,4, Glen Doherty1,3, Jane McCarthy1,2.   

Abstract

Entities:  

Keywords:  Crohn’s disease; IBD; biologics; combined biologics; combined targeted treatment; small molecules; ulcerative colitis

Mesh：

Year:  2021        PMID： 33544119     DOI： 10.1093/ibd/izab028

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  1 in total

1.  Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

Authors:  Laurent Goessens; Jean-Frédéric Colombel; An Outtier; Marc Ferrante; Joao Sabino; Ciaran Judge; Reza Saeidi; Louise Rabbitt; Alessandro Armuzzi; Eugeni Domenech; George Michalopoulos; Anneline Cremer; Francisco Javier García-Alonso; Tamas Molnar; Konstantinos Karmiris; Krisztina Gecse; Joep Van Oostrom; Mark Löwenberg; Klaudia Farkas; Raja Atreya; Davide Giuseppe Ribaldone; Christian Selinger; Frank Hoentjen; Benoit Bihin; Shaji Sebastian; Jean-François Rahier
Journal:  United European Gastroenterol J       Date:  2021-10-25       Impact factor: 4.623
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.